The authors reply

New England Journal of Medicine

Volumn 372, Issue 3, 2015, Pages 291-292

  Cremolini, Chiara ^a   Loupakis, Fotios ^a   Falcone, Alfredo ^b  

^a Universitaria Pisana   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; MONOCLONAL ANTIBODY;

ADVERSE OUTCOME; CANCER INCIDENCE; CANCER SURVIVAL; HUMAN; LETTER; METASTATIC COLORECTAL CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; SALVAGE THERAPY; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; FEMALE; MALE; NEOPLASM METASTASIS;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS;

EID: 84920954757     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1413996     Document Type: Letter

References (4)

1. Shi Q, de Gramont A, Grothey A, et al. Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the Analysis and Research in Cancers of the Digestive System database. J Clin Oncol 2014 November 10 (Epub ahead of print).
2. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-65.
3. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
4. Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014;25:107-16.